The performance values of available techniques used in serodiagnosis of toxoplasmosis are satisfactory but they raise problems of equivocal and discordant results for very low IgG titers. Recently marketed, LDBio-Toxo II IgG Western blot (IB) showed an excellent correlation with the dye test. We estimated the proportion of equivocal and discordant results between the enzyme immunoassay Platelia Toxo IgG (EIA-IgG) and fluorescent antibody test (FAT) and assessed the usefulness of the IB as a confirmatory test. Out of 2,136 sera collected from pregnant women, 1,644 (77.0%) tested unequivocally positive and 407 (19.0%) were negative in both EIA-IgG and FAT. The remaining 85 (4%) sera showed equivocal or discordant results. Among them, 73 (85.9%) were positive and 12 (14.1%) were negative in IB. Forty-one (89.1%) equivocal sera in EIA-IgG and 46 (86.8%) equivocal sera in FAT were positive in IB. Reducing the cut-off values of both screening techniques improved significantly their sensitivity in detecting very low IgG titers at the expense of their specificity. In conclusion, equivocal results in routine-used techniques and their discordance in determination of the immune status in pregnancy women were not uncommon. IB test appeard to be highly useful in these situations as a confirmatory technique.
22 October 2014 in The Korean Journal of Parasitology
: Mucosal leishmaniasis (ML) is a parasitic disease affecting the mucosa of the upper respiratory tract and oral cavity. It is most prevalent in Central and South America, whereas cases in the Old World are relatively rare. Herein, we present the case of an immunocompetent man from Tunisia with a long-delayed diagnosis of ML, characterized by lesions in the nasal mucosa without cutaneous involvement. This report underlines the importance of multidisciplinary care and adherence to follow-up in managing this disease. Clinicians should remain vigilant regarding this parasitosis, its potential complications, and the need for accurate diagnosis and treatment.
Serology is mostly used to diagnose toxoplasmosis by methodically looking for anti-toxoplasmic IgG and IgM. The difference between anti-Toxoplasma IgM and non-specific IgM, referred to as "natural," is one of the challenges in interpreting Toxoplasma serology in pregnant women. This study aimed to assess the diagnostic efficacy of the "recomLine Toxoplasma IgM" immunoblot assay (Mikrogen, Diagnostik) in differentiating between normal IgM and specific anti-Toxoplasma IgM. Tests have been performed on 58 pregnant women's sera. ELISA-IgM was positive for all of these sera, while ELISA-IgG and IFI-IgG were negative. These sera are separated into two categories: Group 1: 30 sera were found to have natural IgM following three-week inspections for a maximum of three months. 28 sera with particular anti-toxoplasmic IgM were in group 2. The recomLine Toxoplasma IgM assay was used by the immunoblot kit to test the 28 sera. The eight recombinant toxoplasmic antigens that this test is based on are ROP1c, MIC3, GRA7, GRA8, p30, MAG1, GRA1, and rSAG1. Of the 28 confirmed IgM-specific sera, 11 had a sensitivity of 39.3% [22.1-59.3] in recomLine Toxoplasma IgM, while 28 of the 30 confirmed natural IgM sera had a specificity of 93.33% [76.5-98.8]. When IgM is positive and IgG is negative, the recomLine Toxoplasma IgM test can be recommended. The test's positive result increases the likelihood of a Toxoplasma seroconversion diagnosis, while its negative result does not rule it out. The test's positive predictive value was 84.6% [53.7-97.3] and its negative predictive value was 62.2% [46.5-75.8].